Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04218695 · ClinicalTrials.gov registry record · Phase 4

Prophylactic Antibiotics in Admitted Cirrhotics

A Phase 4 study of Cirrhosis, Liver, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
Phase 4
Development phase
32
Enrollment target
1
Study location

NCT04218695 is a Phase 4 study of Cirrhosis, Liver that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 32 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04218695, a Phase 4 study of Cirrhosis, Liver, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric antibiotics for all patients with advanced cirrhosis admitted to the hospital without an existing indication for new antibiotic use. Specifically, the investigators will assess the incidence of infection after the time of enrollment and associated outcomes. Subjects will be randomly assigned to receive antibiotics vs placebo.

Conditions Studied

Interventions

  • DRUG Normal saline
  • DRUG Ceftriaxone

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2020-08-24
Est. Completion 2021-08-28
Phase Phase 4

What the Registry Record Tells You About NCT04218695

The ClinicalTrials.gov registry entry for NCT04218695 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (87% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.

NCT04218695 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04218695 about?

NCT04218695 is a clinical study titled "Prophylactic Antibiotics in Admitted Cirrhotics". In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric antibiotics for all patients with advanced cirrhosis admitted to the ho...

What is the current status of trial NCT04218695?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2020-08-24. Estimated completion is 2021-08-28.

What conditions does trial NCT04218695 study?

This clinical trial studies the following conditions: Cirrhosis, Liver.

What interventions are being tested in trial NCT04218695?

The interventions under investigation include: Normal saline (DRUG), Ceftriaxone (DRUG).

Who is sponsoring clinical trial NCT04218695?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04218695 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cirrhosis, Liver

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.